AbbVie Surges 5% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate
AbbVie Surges 5% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate · Investor's Business Daily

In This Article:

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq by $4 billion.